Company description

CELU, ticker symbol for Celularity, Inc., is a clinical-stage biotechnology company that focuses on developing novel cellular therapies for the treatment of cancer and infectious diseases. Founded in 2017, Celularity aims to transform the field of regenerative medicine by harnessing the power of placental-derived cells to create innovative therapies. The company's proprietary platform, Celularity Engineered Pluripotent Stemcells (CEPSC), allows for the expansion and manufacturing of high-quality, scalable cell therapies at a reduced cost compared to traditional methods. Celularity has a pipeline of promising therapies including CYNK-001, a natural killer cell therapy currently being evaluated in clinical trials for hematologic and solid tumor malignancies. The company has also formed strategic partnerships with major pharmaceutical companies and has received significant funding from prominent investors. With a strong management team and a dedication to advancing groundbreaking therapies, Celularity is poised to be a major player in the field of regenerative medicine.